Usana Health Sciences IncUSNA
Price$14.47

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value not published yet, our data-reliability standards weren't met; method estimates belowbased on filings through 4 Jul 2026
Market Price $14.47Price as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 22.5% (near-term consensus, capped) · years 2–5: -22.4%/yr (balance of the path).-15.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 6-17.3%Yr 7-12.3%Yr 8-7.2%Yr 9-2.1%Yr 103.0%
-22.4% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/7y) (limited history)-31.1%
Discount rate (cost of equity) 8.6%
Volatility vs market (adjusted beta)0.82

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetUsana Health Sciences IncUSNAConsumer Staples
Valuation
P/E—
P/S0.3×
P/B0.5×
EV / Revenue0.1×
EV / EBITDA3.2×
Profitability
Gross margin77.4%
Operating margin-0.1%
Net margin-2.4%
FCF margin1.7%
Returns
ROE-4.2%
ROA-3.2%
ROIC—
Growth
Revenue growth (YoY)6.9%
5-yr fwd EPS growth—
Financial strength
Debt / Equity0.03×
Current ratio2.66×
Altman Z-Score3.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.